Первичная гипертрофическая остеоартропатия
Аннотация
Представлены сведения о редком наследственном заболевании – первичной гипертрофической остеоартропатии с аутосомно-доминантным и аутосомно-рецессивным наследованием. Генетическая гетерогенность обусловливает клинический полиморфизм симптомов, появляющихся в детском и подростковом возрасте. Дифференциальную диагностику необходимо проводить со вторичной гипертрофической остеоартропатией, встречающейся в 90% случаев и ассоциированной со злокачественными новообразованиями, ревматическими болезнями и другими заболеваниями. Важное значение отводится рентгенологическим признакам, позволяющим уточнить локализацию, протяженность и характер поражения костей. Специфическое лечение заболевания отсутствует.
Ключевые слова
Об авторе
Е. Л. Трисветова
УО «Белорусский государственный медицинский университет»
Беларусь
Беларусь
Трисветова Евгения Леонидовна
220116, Минск, пр. Дзержинского, д. 83
Список литературы
1. Castori M., Sinibaldi L., Mingarelli R., et al. Pachydermoperiostosis: an update. Clin Genet. 2005;68(6):477–486. DOI: 10.1111/j.1399-0004.2005.00533.x
2. Zhang Z., Zhang C., Zhang Zh. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013;7(1):60–64. DOI: 10.1007/s11684-013-0246-6
3. Yap F.Y., Skalski M.R., Patel D.B., et al. Hypertrophic Osteoarthropathy: RadioGraphics. 2017;37(1):157–195. DOI: 10.1148/rg.2017160052
4. Jajic I., Jajic Z. Prevalence of primary hypertrophic osteoarthropathy in selected population. Clin Exp Rheumatol. 1992;10(2):73.
5. Giancane G., Diggle C.P., Legger E.G., et al. Primary hypertrophic osteoarthropathy: an update on patient features and treatment. J Rheumatol. 2015;42(11):2211–2214. DOI: 10.3899/jrheum.150364
6. Uppal S., Diggle C.P., Carr I.M., et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet. 2008;40(6):789–793. DOI: 10.1038/ng.153
7. Sasaki T., Niizeki H., Shimizu A., et al. Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype–genotype correlation in Japanese patients with pachydermoperiostosis. J Dermatol Sci. 2012;68(1):36–44. DOI: 10.1016/j.jdermsci.2012.07.008
8. Zhang Z., He J.W., Fu W.Z., et al. Mutations in the SLCO2A1 gene and primary hypertrophic osteoarthropathy: a clinical and biochemical characterization. J Clin Endocrinol Metab. 2013;98(5):E923–933. DOI: 10.1210/jc.2012-3568
9. Treasure T. Hypertrophic pulmonary osteoarthropathy and the vagus nerve: an historical note. J R Soc Med. 2006;99(8):388–390. DOI: 10.1258/jrsm.99.8.388
10. Yao Q., Altman R.D., Brahn E. Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature. Semin Arthritis Rheum. 2009;38(6):458–466. DOI: 10.1016/j.semarthrit.2008.07.001
11. Seifert W., Kuhnisch J., Tuysuz B., et al. Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. Hum Mutat. 2012;33(4):660–664. DOI: 10.1002/humu.22042
12. Diggle C.P., Parry D.A., Logan C.V., et al. Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Hum Mutat. 2012;33(8):1175–1181. DOI: 10.1002/humu.22111
13. Matucci-Cerinic M., Lotti T., Jajic I., et al. The clinical spectrum of pachydermoperiostosis (primary hypertrophic osteoarthropathy). Medicine. 1991;70(3):208–214.
14. Martínez-Lavín M., Pineda C., Valdez T., et al. Primary hypertrophic osteoarthropathy. Semin Arthritis Rheum. 1988;17(3):156–162. DOI: 10.1016/0049-0172(88)90017-0
15. Li S.-S., He G.-W., Fu W.-Z., et al. Clinical, Biochemical, and Genetic Features of 41 Han Chinese Families With Primary Hypertrophic Osteoarthropathy, and Their Therapeutic Response to Etoricoxib: Results From a Six-Month Prospective Clinical Intervention. J Bone Miner Res. 2017;32(8):1659–1666. DOI:10.1002/jbmr.3157
16. Korsten P., Bohnenberger H., Vasko R. Hypertrophic osteoarhropathy presenting as inflammatory arthritis. Arthritis Rheumatol. 2015;67(11):3036. DOI: 10.1002/art.39272
17. Padula S.J., Broketa G., Sampieri A., et al. Increased collagen synthesis in skin fibroblasts from patients with primary hypertrophic osteoarthropathy. Evidence for trans activational regulation of collagen transcription. Arthritis Rheum. 1994;37(9):1386–1394. DOI: 10.1002/art.1780370918
18. Rana R.S., Wu J.S., Eisenberg R.L. Periosteal reaction. AJR Am J Roentgenol. 2009;193(4):W259–W272. DOI: 10.2214/AJR.09.3300
19. Jajic Z., Jajic I., Nemcic T. Primary hypertrophic osteoarthropathy: clinical, radiologic, and scintigraphic characteristics. Arch Med Res. 2001;32(2):136–142. DOI: 10.1016/s0188-4409(01)00251-x
20. Capelastegui A., Astigarraga E., García-Iturraspe C. MR findings in pulmonary hypertrophic osteoarthropathy. Clin Radiol. 2000;55(1):72–75. DOI: 10.1053/crad.1999.0101
21. Santhosh S., Bhattacharya A., Bhadada S., et al. Three-phase skeletal scintigraphy in pachydermoperiostosis. Clin Nucl Med. 2011;36(12):e199–e201. DOI: 10.1097/RLU.0b013e3182291ee0
22. Aparici C.M., Bains S. Hypertrophic osteoarthropathy seen with NaF18 PET/CT bone imaging. Clin Nucl Med. 2011;36(10):928–929. DOI: 10.1097/RLU.0b013e31821a2728
23. Bozzao F., Bernardi S., Dore F., et al. Hypertrophic osteoarthropathy mimicking a reactive arthritis: a case report and review of the literature. BMC Musculoscelet Disord. 2018;19:145. DOI: 10.1186/s12891-018-2068-9
24. Diamond S., Momeni M. Primary hypertrophic osteoarthropathy in a patient with rheumatoid arthritis. J Clin Rheumatol. 2007;13(4):242–243. DOI: 10.1097/RHU.0b013e31812e00b3
25. Armstrong D.J., McCausland E.M., Wright G.D. Hypertrophic pulmonary osteoarthropathy (HPOA) (Pierre Marie-Bamberger syndrome): two cases presenting as acute inflammatory arthritis. Description and review of the literature. Rheumatol Int. 2007;27(4):399–402. DOI: 10.1007/s00296-006-0224-2
26. Aluoch A.O., Farbman M., Gladue H. An unusual mimicker of systemic lupus erythematosus: a case report. Open Rheumatol J. 2015;9:27–29. DOI: 10.2174/18743129014090100027
27. Shinjo S.K., Borba E., Goncalves C.R., et al. Ankylosing spondylitis in a patient with primary hypertrophic osteoarthropathy. J Clin Rheumatol. 2007;13(3):175. DOI: 10.1097/RHU.0b013e3180690b97
28. Ihde L.L., Forrester D.M., Gottsegen C.J., et al. Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics. 2011;31(7):1865–1882. DOI: 10.1148/rg.317115093
29. Pineda C., Martínez-Lavín M. Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition. Rheum Dis Clin. North Am. 2013;39(2):383–400. DOI: 10.1016/j.rdc.2013.02.008
30. Bucknor M.D., Gross A.J., Link T.M. Voriconazole-induced periostitis in two post-transplant patients. J Radiol Case Rep. 2013;7(8):10–17. DOI: 10.3941/jrcr.v7i8.1458
31. Lucas-Fehm L.M., Makler P.T. Jr, Shapiro B. Technetium-99m MDP uptake in chronic venous insufficiency. Clin Nucl Med. 1986;11(11):803.
32. Wendling D., Hafsaoui C., Laurain J.M., et al. Dysphagia and hypervitaminosis A: cervical hyperostosis. Joint Bone Spine. 2009;76(4):409–411. DOI: 10.1016/j.jbspin.2008.11.004
33. Shakya P., Pokhrel K., Mlunde L.B., et al. Effectiveness of nonsteroidal anti-inflammatory drugs among patients with primary hypertrophic osteoarthropathy: A systematic review. J Dermatol Sci. 2018;90(1):21–26. DOI: 10.1016/j.jdermsci.2017.12.012
34. DaCosta F.V., de Magalhães Souza Fialho S.C., Zimmermann A.F., et al. Infliximab treatment in pachydermoperiostosis: a rare disease without an effective therapeutic option. J Clin Rheumatol. 2010;16(4):183–184. DOI: 10.1097/rhu.0b013e3181df91c6
35. Kikuchi R., Itoh M., Tamamushi M., et al. Hypertrophic Osteoarthropathy Secondary to Lung Cancer: Beneficial Effect of Anti-vascular Endothelial Growth Factor Antibody. J Clin Rheumatol. 2017;23(1):47–50. DOI: 10.1097/RHU.0000000000000441
Рецензия
Для цитирования:
Трисветова Е.Л. Первичная гипертрофическая остеоартропатия. Научно-практическая ревматология. 2020;58(5):544-549. https://doi.org/10.47360/1995-4484-2020-544-549
For citation:
Trisvetova E.L. Primary hypertrophic osteoarthropathy. Rheumatology Science and Practice. 2020;58(5):544-549. (In Russ.) https://doi.org/10.47360/1995-4484-2020-544-549
Просмотров: 808
Послать статью по эл. почте 
